Latest Insider Transactions at Aprea Therapeutics, Inc. (APRE)
This section provides a real-time view of insider transactions for Aprea Therapeutics, Inc. (APRE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aprea Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aprea Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.15%
|
$1,500
$3.92 P/Share
|
|
Oct 18
2024
|
Marc Duey Director |
SELL
Open market or private sale
|
Direct |
6,462
-2.69%
|
$25,848
$4.58 P/Share
|
|
Oct 16
2024
|
Marc Duey Director |
BUY
Open market or private purchase
|
Direct |
30,000
+11.11%
|
$120,000
$4.39 P/Share
|
|
Oct 15
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
250
+0.08%
|
$500
$2.9 P/Share
|
|
Oct 14
2024
|
Marc Duey Director |
BUY
Open market or private purchase
|
Direct |
190
+0.09%
|
$380
$2.58 P/Share
|
|
Oct 14
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.3%
|
$2,000
$2.59 P/Share
|
|
Oct 11
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
50
+0.26%
|
$100
$2.46 P/Share
|
|
Oct 11
2024
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+18.27%
|
$20,000
$2.68 P/Share
|
|
Oct 10
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
450
+2.28%
|
$900
$2.61 P/Share
|
|
Oct 10
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
150
+0.05%
|
$300
$2.54 P/Share
|
|
Jun 20
2024
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+2.92%
|
-
|
|
Jun 20
2024
|
Marc Duey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+0.5%
|
-
|
|
Jun 20
2024
|
Michael Grissinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+36.17%
|
-
|
|
Jun 20
2024
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+10.22%
|
-
|
|
Jun 20
2024
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+33.5%
|
-
|
|
Jun 20
2024
|
Rifat Pamukcu Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,045
+19.19%
|
-
|
|
May 01
2024
|
Nadeem Q. Mirza Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,730
+50.0%
|
-
|
|
Mar 28
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
3,365
+15.14%
|
-
|
|
Mar 28
2024
|
Oren Gilad President/CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,725
+1.99%
|
-
|
|
Mar 13
2024
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Open market or private purchase
|
Direct |
1,010
+6.12%
|
$7,070
$7.29 P/Share
|
|
Mar 13
2024
|
Oren Gilad President/CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.61%
|
$14,000
$7.29 P/Share
|
|
Mar 13
2024
|
John B Henneman Iii Director |
BUY
Open market or private purchase
|
Direct |
6,860
+45.74%
|
$48,020
$7.29 P/Share
|
|
Mar 13
2024
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
6,860
+16.92%
|
$48,020
$7.29 P/Share
|
|
Aug 23
2023
|
Marc Duey Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+0.24%
|
-
|
|
Aug 23
2023
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+32.7%
|
-
|
|
Aug 23
2023
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+28.11%
|
-
|
|
Aug 23
2023
|
Michael Grissinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+38.49%
|
-
|
|
Aug 23
2023
|
Rifat Pamukcu Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+12.97%
|
-
|
|
Aug 23
2023
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+1.83%
|
-
|
|
Jun 07
2023
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
6,029
+18.63%
|
$18,087
$3.68 P/Share
|
|
Jun 06
2023
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
4,068
+16.7%
|
$12,204
$3.63 P/Share
|
|
Mar 09
2023
|
Oren Gilad President/CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+1.22%
|
-
|
|
Feb 27
2023
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+6.45%
|
$5,000
$5.25 P/Share
|
|
Jan 30
2023
|
John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
269,879
+50.0%
|
-
|
|
Aug 23
2022
|
Marc Duey Director |
BUY
Conversion of derivative security
|
Indirect |
11,610
+95.07%
|
-
|
|
Aug 23
2022
|
Marc Duey Director |
BUY
Conversion of derivative security
|
Direct |
4,009,690
+49.03%
|
-
|
|
Aug 23
2022
|
Rifat Pamukcu Director |
BUY
Conversion of derivative security
|
Indirect |
271,870
+95.07%
|
-
|
|
Aug 23
2022
|
Rifat Pamukcu Director |
BUY
Conversion of derivative security
|
Direct |
49,280
+46.31%
|
-
|
|
Aug 23
2022
|
Oren Gilad President/CEO |
BUY
Conversion of derivative security
|
Direct |
6,045,100
+48.67%
|
-
|
|
Jul 28
2022
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+1.81%
|
-
|
|
Jul 28
2022
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,400
+11.11%
|
-
|
|
Jul 28
2022
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+36.11%
|
-
|
|
Jul 28
2022
|
Rifat Pamukcu Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+43.26%
|
-
|
|
Jul 28
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+34.68%
|
-
|
|
Jul 28
2022
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+27.75%
|
-
|
|
Jul 28
2022
|
Michael Grissinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+50.0%
|
-
|
|
Jul 28
2022
|
Oren Gilad President/CEO |
BUY
Grant, award, or other acquisition
|
Direct |
101,300
+23.47%
|
-
|
|
Jul 28
2022
|
Marc Duey Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,995
+3.66%
|
-
|
|
Jul 28
2022
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+29.53%
|
-
|
|
Jun 03
2022
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,667
-36.34%
|
$0
$0.8 P/Share
|